Researcher.Life Logo

Vaccine: X : Impact Factor & More

eISSN: 2590-1362pISSN: 2590-1362
JournalOpen Access

Key Metrics

CiteScore
3.9
SNIP
1.81
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Vaccine: X

Vaccine: X Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher ELSEVIER
Language English
Frequency Tri-annual
Article Processing ChargesUSD 2000
Publication Time13
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyTri-annual
Publication Start Year2019
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 13
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Vaccine: X ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Vaccine: X

COVID-19 vaccine adverse events in indigenous communities in Northwest Territories, Canada
  • 1 Jun 2026
  • Vaccine: X
Impact and cost-effectiveness of maternal vaccine and short and long-acting monoclonal antibodies against respiratory syncytial virus among children in Japan: A modeling study
  • 1 Jun 2026
  • Vaccine: X
The comparison of Immune response to Third booster dose with of Vaxzevria or Comirnaty COVID-19 vaccine in healthcare workers after receiving two doses of CoronaVac
  • 1 Jun 2026
  • Vaccine: X
Association between village coverage of 13-valent pneumococcal conjugate vaccine and vaccine-type pneumococcal carriage among children aged 0–59 months with pneumonia in Papua New Guinea: an observational study
  • 1 Jun 2026
  • Vaccine: X
“Every time I had to pay $50, it was adding up, but there was no option”: A qualitative study with parents and primary caregivers in Australia on barriers to timely childhood vaccination
  • 1 Jun 2026
  • Vaccine: X
Active surveillance of adverse events following immunisation in children: pre, during and post COVID-19 pandemic
  • 1 Jun 2026
  • Vaccine: X
COVID-19 vaccine adverse events in indigenous communities in Northwest Territories, Canada
  • 1 Jun 2026
  • Vaccine: X
Impact and cost-effectiveness of maternal vaccine and short and long-acting monoclonal antibodies against respiratory syncytial virus among children in Japan: A modeling study
  • 1 Jun 2026
  • Vaccine: X
The comparison of Immune response to Third booster dose with of Vaxzevria or Comirnaty COVID-19 vaccine in healthcare workers after receiving two doses of CoronaVac
  • 1 Jun 2026
  • Vaccine: X
Association between village coverage of 13-valent pneumococcal conjugate vaccine and vaccine-type pneumococcal carriage among children aged 0–59 months with pneumonia in Papua New Guinea: an observational study
  • 1 Jun 2026
  • Vaccine: X
“Every time I had to pay $50, it was adding up, but there was no option”: A qualitative study with parents and primary caregivers in Australia on barriers to timely childhood vaccination
  • 1 Jun 2026
  • Vaccine: X
Active surveillance of adverse events following immunisation in children: pre, during and post COVID-19 pandemic
  • 1 Jun 2026
  • Vaccine: X

FAQs on Vaccine: X